Immunotherapy and radiation before lung surgery for osteosarcoma
Part of Cancer clinical trials.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have osteosarcoma (a type of bone cancer) that has spread to your lungs, but not come back at the original bone site.
- The lung spots must be able to be removed by surgery (like a wedge or segment removal) without taking out the whole lung.
- You need to have had at least one standard chemotherapy treatment for your cancer and never taken the drug gemcitabine.
- Your lungs must be healthy enough for you to undergo surgery.
- You must be between 10 and 65 years old.
- You should be able to take care of yourself (like with a walker or wheelchair if needed) and expected to live more than 24 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, envafolimab, combined with chemotherapy before surgery for patients with a type of bone cancer called osteosarcoma that has not spread. The goal is to see if this approach can improve the chance of removing the tumor successfully and reducing the risk of it coming back.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This trial tests removing the tumor with surgery first, then following up with chemotherapy. It's for people with a new, high-grade osteosarcoma in an arm or leg that hasn't spread.
This Phase 3 trial compares two ways to remove lung metastases (open surgery vs keyhole surgery) in people with osteosarcoma. It aims to see which approach works better and is safer for patients with a limited number of lung spots that can be removed.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.